--- title: "花旗銀行維持對安進(AMGN)的持有評級" description: "根據 TipRanks 的數據,Meacham 是一位四星分析師,平均回報率為 4.2%,成功率為 55.14%。Meacham 覆蓋醫療保健行業,專注於如禮來公司(Eli Lilly & Co)、安進(Amgen)和 Vertex 製藥等股票。除了花旗集團,安進在 10 月 10 日的報告中也獲得了 Raymond James 的 Christopher Raymond 的持有評級。然而,在 1" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/260882086.md" published_at: "2025-10-13T10:55:50.000Z" --- # 花旗銀行維持對安進(AMGN)的持有評級 > 根據 TipRanks 的數據,Meacham 是一位四星分析師,平均回報率為 4.2%,成功率為 55.14%。Meacham 覆蓋醫療保健行業,專注於如禮來公司(Eli Lilly & Co)、安進(Amgen)和 Vertex 製藥等股票。除了花旗集團,安進在 10 月 10 日的報告中也獲得了 Raymond James 的 Christopher Raymond 的持有評級。然而,在 10 月 8 日,RBC Capital 對安進(NASDAQ: AMGN)維持了買入評級 根據 TipRanks 的數據,Meacham 是一位 4 星分析師,平均回報率為 4.2%,成功率為 55.14%。Meacham 覆蓋醫療保健行業,關注的股票包括禮來公司、安進和 Vertex 製藥。 除了花旗,安進在 10 月 10 日的報告中也獲得了 Raymond James 的 Christopher Raymond 的持有評級。然而,在 10 月 8 日,RBC Capital 維持了對安進(NASDAQ: AMGN)的買入評級。 ### Related Stocks - [AMGN.US - 安進](https://longbridge.com/zh-HK/quote/AMGN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update | Amgen executives discussed upcoming clinical milestones and data updates in their inflammation and immunology portfolio. | [Link](https://longbridge.com/zh-HK/news/275831709.md) | | Amgen receives EC approval for Uplizna in generalised myasthenia gravis | Amgen has received European Commission approval for Uplizna (inebilizumab) as an add-on treatment for adults with genera | [Link](https://longbridge.com/zh-HK/news/275884466.md) | | REG - Morgan Stanley&CoLLC Avadel Pharma plc - Rule 38.5_A - Avadel Pharmaceuticals plc | Morgan Stanley & Co. LLC disclosed dealings related to Avadel Pharmaceuticals plc under Rule 38.5(a) of the Irish Takeov | [Link](https://longbridge.com/zh-HK/news/275721511.md) | | Where Were The Job Opportunities In 2025? Where Will They Be In 2026? | In 2025, job growth was minimal, with only Education and Health Care (+697,000 jobs) and Leisure and Hospitality (+119,0 | [Link](https://longbridge.com/zh-HK/news/275986113.md) | | REG - Rubric Capital Mgmt Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc | Rubric Capital Management LP disclosed its position in Avadel Pharmaceuticals plc under Rule 8.3 of the Irish Takeover P | [Link](https://longbridge.com/zh-HK/news/275770954.md) | --- > **免責聲明**:本文內容僅供參考,不構成任何投資建議。